Iridium Corporation logo

Iridium Corporation (IRMD)

Market Closed
17 Jul, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
97. 03
-0.74
-0.7569%
$
1.24B Market Cap
34.27 P/E Ratio
0.8% Div Yield
129,700 Volume
1.49 Eps
$ 97.77
Previous Close
Add Transaction
Day Range
96.25 97.94
Year Range
55.11 107.9
Want to track IRMD and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
IRADIMED CORPORATION (IRMD) Q1 2026 Earnings Call Transcript

IRADIMED CORPORATION (IRMD) Q1 2026 Earnings Call Transcript

IRADIMED CORPORATION (IRMD) Q1 2026 Earnings Call Transcript

Seekingalpha | 2 months ago
iRadimed (IRMD) Beats Q1 Earnings and Revenue Estimates

iRadimed (IRMD) Beats Q1 Earnings and Revenue Estimates

iRadimed (IRMD) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.42 per share a year ago.

Zacks | 2 months ago
IRADIMED CORPORATION (IRMD) Q3 2025 Earnings Call Transcript

IRADIMED CORPORATION (IRMD) Q3 2025 Earnings Call Transcript

IRADIMED CORPORATION ( IRMD ) Q3 2025 Earnings Call November 3, 2025 11:00 AM EST Company Participants Roger Susi - Founder, Chairman, CEO & President John Glenn - CFO & Corporate Secretary Conference Call Participants Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Kyle Bauser - ROTH Capital Partners, LLC, Research Division Presentation Operator Welcome to the IRADIMED CORPORATION Third Quarter 2025 Financial Results Conference Call. [Operator Instructions] This call is being recorded today, November 3, 2025, and contains time-sensitive accurate information that is valid only for today.

Seekingalpha | 8 months ago
IRadimed: Continued Value Unlock With Extensive Reinvestment Runway

IRadimed: Continued Value Unlock With Extensive Reinvestment Runway

IRadimed Corporation demonstrates exceptional economic characteristics, with high NOPAT margins, robust free cash flow, and consistent value creation for shareholders. Management has effectively reinvested capital, generating over $18 in market value for every $1 invested since FY'22, and consistently exceeding a 12% ROIC hurdle rate. Despite modest sales growth, IRMD's profitability and cash conversion remain strong, with a persistent ability to redeploy earnings at attractive returns.

Seekingalpha | 11 months ago
Recent Price Trend in iRadimed (IRMD) is Your Friend, Here's Why

Recent Price Trend in iRadimed (IRMD) is Your Friend, Here's Why

iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks | 11 months ago
IRADIMED CORPORATION (IRMD) Q2 2025 Earnings Call Transcript

IRADIMED CORPORATION (IRMD) Q2 2025 Earnings Call Transcript

IRADIMED CORPORATION (NASDAQ:IRMD ) Q2 2025 Earnings Conference Call August 1, 2025 11:00 AM ET Company Participants John F. Glenn - CFO & Corporate Secretary Roger E.

Seekingalpha | 11 months ago
iRadimed (IRMD) Q2 Earnings and Revenues Surpass Estimates

iRadimed (IRMD) Q2 Earnings and Revenues Surpass Estimates

iRadimed (IRMD) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.42 per share a year ago.

Zacks | 11 months ago
New Strong Sell Stocks for June 12th

New Strong Sell Stocks for June 12th

LYB, IRMD and SONY have been added to the Zacks Rank #5 (Strong Sell) List on June 12, 2025.

Zacks | 1 year ago
IRADIMED CORPORATION (IRMD) Q1 2025 Earnings Call Transcript

IRADIMED CORPORATION (IRMD) Q1 2025 Earnings Call Transcript

IRADIMED CORPORATION (NASDAQ:IRMD ) Q1 2025 Earnings Conference Call May 5, 2025 9:00 AM ET Company Participants Roger Susi - Founder, President & CEO John Glenn - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Operator Welcome to the IRADIMED Corporation First Quarter of 2025 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

Seekingalpha | 1 year ago
IRadimed (IRMD) Lags Q1 Earnings Estimates

IRadimed (IRMD) Lags Q1 Earnings Estimates

IRadimed (IRMD) came out with quarterly earnings of $0.42 per share, missing the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.36 per share a year ago.

Zacks | 1 year ago
IRadimed Corporation: Steady, Low-Risk Grower In The Devices Space

IRadimed Corporation: Steady, Low-Risk Grower In The Devices Space

IRadimed Corporation offers steady revenue growth with 14 consecutive quarters of record revenue and a small dividend, despite recent stock price decline. IRMD's unique MRI-compatible IV infusion pump and patient monitoring system face limited competition, ensuring a strong market position. Financials show robust performance with a 21% increase in US sales, but international sales dipped possibly due to cheaper alternatives in Asian markets.

Seekingalpha | 1 year ago
IRADIMED CORPORATION (IRMD) Q4 2024 Earnings Call Transcript

IRADIMED CORPORATION (IRMD) Q4 2024 Earnings Call Transcript

IRADIMED CORPORATION (NASDAQ:IRMD ) Q4 2024 Earnings Conference Call February 13, 2025 11:00 AM ET Company Participants Roger Susi - Founder, President and CEO John Glenn - Chief Financial Officer Conference Call Participants Jason Wittes - ROTH Capital Partners Nelson Cox - Lake Street Capital Markets Operator Welcome to the IRADIMED CORPORATION Fourth Quarter of 2024 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

Seekingalpha | 1 year ago
Loading...
Load More